A new option for relapsed or refractory acute lymphoblastic leukemia

Boston Children’s Hospital now offers a precision, FDA-approved treatment to children, teens, and young adults (up to age 25) with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (ALL). It alters the immune system’s T cells genetically so they can better detect and destroy cancerous cells.‬

See if you or your loved one might be eligible. Our care team welcomes patients from around the world.